Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284485 · ClinicalTrials.gov registry record · Phase 2
Immunoprevention for High-risk Lung Lesions
A Phase 2 study of High-risk Lung Nodules, sponsored by Robert Samstein.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT07284485 is a Phase 2 study of High-risk Lung Nodules that is actively recruiting participants, run by Robert Samstein. The registered enrollment target is 59 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07284485, a Phase 2 study of High-risk Lung Nodules, is actively recruiting participants, sponsored by Robert Samstein.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
Conditions Studied
Interventions
- BIOLOGICAL Nadunolimab
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2029-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07284485
The ClinicalTrials.gov registry entry for NCT07284485 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Robert Samstein, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-risk Lung Nodules appearing as the primary indexed condition, and to 1 intervention - of which Nadunolimab is the first listed.
NCT07284485 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07284485 about?
NCT07284485 is a clinical study titled "Immunoprevention for High-risk Lung Lesions". The main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
What is the current status of trial NCT07284485?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2026-04-01. Estimated completion is 2029-12-17.
What conditions does trial NCT07284485 study?
This clinical trial studies the following conditions: High-risk Lung Nodules.
What interventions are being tested in trial NCT07284485?
The interventions under investigation include: Nadunolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT07284485?
This trial is sponsored by Robert Samstein, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284485 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.